

Applicant: Erik Buntinx
Serial No.: 10/803,793
Filed: March 18, 2004
Page 2


Claims 49, 50, 54, 55, 59, 60, 68, 72, 76 and 85-91, drawn to a pharmaceutical composition. With respect to the species election, applicant notes that the pharmaceutical composition claims include two or three compounds. With respect to the claims referring to two compounds, applicant elects Levopoda/Carbidopa as the second compound (reads on Claims 54, 55, and 89). With respect to the claims referring to three compounds, applicant elects pipamperone and pergolide as the second and third compounds, respectively (reads on Claim 68). With respect to the disease or disorder, applicant elects Parkinson Disease (reads on Claims 54, 55, 68 and 89).

No fee is deemed necessary in connection with the submission of this Communication. However, if any fee is required to maintain the pendency of the subject application, authorization is hereby given to withdraw the amount of any such fee from Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: March 14, 2007
New York, New York

By 
Craig J. Arnold, Reg. No. 34,287